A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Condition:   Anemia, Sickle Cell Intervention:   Drug: HBI-002 Sponsors:   Hillhurst Biopharmaceuticals, Inc.;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials